{"id":62112,"date":"2025-01-01T00:00:00","date_gmt":"2025-01-01T00:00:00","guid":{"rendered":"https:\/\/ibima.eu\/zanidatamab-plus-palbociclib-and-fulvestrant-in-previously-treated-patients-with-hormone-receptor-positive-her2-positive-metastatic-breast-cancer-primary-results-from-atwo-part-multicentre-single\/"},"modified":"2025-01-01T00:00:00","modified_gmt":"2025-01-01T00:00:00","slug":"zanidatamab-plus-palbociclib-and-fulvestrant-in-previously-treated-patients-with-hormone-receptor-positive-her2-positive-metastatic-breast-cancer-primary-results-from-atwo-part-multicentre-single","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/zanidatamab-plus-palbociclib-and-fulvestrant-in-previously-treated-patients-with-hormone-receptor-positive-her2-positive-metastatic-breast-cancer-primary-results-from-atwo-part-multicentre-single\/","title":{"rendered":"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from atwo-part, multicentre, single-arm, phase 2a study"},"content":{"rendered":"","protected":true},"excerpt":{"rendered":"","protected":true},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1592],"tags":[],"class_list":["post-62112","post","type-post","status-publish","format-standard","post-password-required","hentry","category-publicaciones-b-01"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from atwo-part, multicentre, single-arm, phase 2a study - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/zanidatamab-plus-palbociclib-and-fulvestrant-in-previously-treated-patients-with-hormone-receptor-positive-her2-positive-metastatic-breast-cancer-primary-results-from-atwo-part-multicentre-single\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from atwo-part, multicentre, single-arm, phase 2a study - Ibima\" \/>\n<meta property=\"og:description\" content=\"No hay extracto porque es una entrada protegida.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/zanidatamab-plus-palbociclib-and-fulvestrant-in-previously-treated-patients-with-hormone-receptor-positive-her2-positive-metastatic-breast-cancer-primary-results-from-atwo-part-multicentre-single\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-01T00:00:00+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/zanidatamab-plus-palbociclib-and-fulvestrant-in-previously-treated-patients-with-hormone-receptor-positive-her2-positive-metastatic-breast-cancer-primary-results-from-atwo-part-multicentre-single\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/zanidatamab-plus-palbociclib-and-fulvestrant-in-previously-treated-patients-with-hormone-receptor-positive-her2-positive-metastatic-breast-cancer-primary-results-from-atwo-part-multicentre-single\\\/\",\"name\":\"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from atwo-part, multicentre, single-arm, phase 2a study - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-01-01T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/zanidatamab-plus-palbociclib-and-fulvestrant-in-previously-treated-patients-with-hormone-receptor-positive-her2-positive-metastatic-breast-cancer-primary-results-from-atwo-part-multicentre-single\\\/#breadcrumb\"},\"inLanguage\":\"es\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from atwo-part, multicentre, single-arm, phase 2a study - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/zanidatamab-plus-palbociclib-and-fulvestrant-in-previously-treated-patients-with-hormone-receptor-positive-her2-positive-metastatic-breast-cancer-primary-results-from-atwo-part-multicentre-single\/","og_locale":"es_ES","og_type":"article","og_title":"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from atwo-part, multicentre, single-arm, phase 2a study - Ibima","og_description":"No hay extracto porque es una entrada protegida.","og_url":"https:\/\/ibima.eu\/es\/zanidatamab-plus-palbociclib-and-fulvestrant-in-previously-treated-patients-with-hormone-receptor-positive-her2-positive-metastatic-breast-cancer-primary-results-from-atwo-part-multicentre-single\/","og_site_name":"Ibima","article_published_time":"2025-01-01T00:00:00+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ibima.eu\/zanidatamab-plus-palbociclib-and-fulvestrant-in-previously-treated-patients-with-hormone-receptor-positive-her2-positive-metastatic-breast-cancer-primary-results-from-atwo-part-multicentre-single\/","url":"https:\/\/ibima.eu\/zanidatamab-plus-palbociclib-and-fulvestrant-in-previously-treated-patients-with-hormone-receptor-positive-her2-positive-metastatic-breast-cancer-primary-results-from-atwo-part-multicentre-single\/","name":"Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from atwo-part, multicentre, single-arm, phase 2a study - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-01-01T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/ibima.eu\/zanidatamab-plus-palbociclib-and-fulvestrant-in-previously-treated-patients-with-hormone-receptor-positive-her2-positive-metastatic-breast-cancer-primary-results-from-atwo-part-multicentre-single\/#breadcrumb"},"inLanguage":"es"},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/62112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=62112"}],"version-history":[{"count":0,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/62112\/revisions"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=62112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=62112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=62112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}